scroll to top
0

EBSCO Auth Banner

Let's find your institution. Click here.

Advanced Search Results For "Abani, Obbina"

Filter
1 - 5 of 5 results for
 "Abani, Obbina"
Results per page:
Sort By:
Your filters
  • Filter by:
  • Source Type: Magazines
  • Reset filters

    • Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

    Publication Type: Periodical

    Source(s): The Lancet; July-August 2022, Vol. 400 Issue: 10349 p359-368, 10p

    Abstract: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.

    Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Publication Type: Periodical

    Source(s): The Lancet; February 2022, Vol. 399 Issue: 10325 p665-676, 12p

    Abstract: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety o...

    Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Publication Type: Periodical

    Source(s): The Lancet; January 2022, Vol. 399 Issue: 10320 p143-151, 9p

    Abstract: Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients admitted to hospital with COVID-19.

    Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

    Publication Type: Periodical

    Source(s): The Lancet; May-June 2021, Vol. 397 Issue: 10289 p2049-2059, 11p

    Abstract: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.

    Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Publication Type: Periodical

    Source(s): The Lancet; May 2021, Vol. 397 Issue: 10285 p1637-1645, 9p

    Abstract: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.

    sponsored